Atom Investors LP Macrogenics Inc Transaction History

Atom Investors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $88,840 - $496,808	-26,840 Reduced 25.6%	78,005 $331,000
Q1 2024 May 15, 2024	SELL	$9.77 - $21.47 $334,573 - $735,240	-34,245 Reduced 24.62%	104,845 $1.54 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $490,295 - $1.11 Million	109,441 Added 369.12%	139,090 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $132,827 - $183,527	29,649 New	29,649 $138,000
Q3 2022 Nov 08, 2022	BUY	$3.01 - $5.22 $138,604 - $240,370	46,048 New	46,048 $159,000
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $1.14 Million - $1.99 Million	-55,863 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$18.99 - $33.2 $1.93 Million - $3.37 Million	-101,589 Reduced 64.52%	55,863 $1.78 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $2.23 Million - $2.98 Million	114,723 Added 268.49%	157,452 $3.6 Million
Q3 2020 Nov 13, 2020	BUY	$24.69 - $31.6 $192,582 - $246,480	7,800 Added 22.33%	42,729 $1.08 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $181,630 - $1.02 Million	34,929 New	34,929 $975,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

Stay updated on Atom Investors LP with notifications on news.